// ─── DEMO TICKERS (fallback when backend is offline) ───
export const DEMOS = {
    HIMS: {
        meta: { ticker: "HIMS", company_name: "Hims & Hers Health, Inc.", sector: "Healthcare / Telehealth", current_price: "$15.80", market_cap: "$3.6B", trailing_pe: "30.86", forward_pe: "22.50", fifty_two_week_range: "$15.63 - $72.98", avg_volume: "46.75M", beta: "1.2", report_date: "Feb 13, 2026", data_freshness_note: "Market close Feb 12, 2026" },
        step_1_know_what_you_own: { one_liner: "Hims sells prescription medications online — you chat with a doctor on your phone, and pills arrive by mail.", how_it_makes_money: "Monthly subscriptions for prescription drugs (hair loss, ED, skincare, weight loss). Cash-pay, no insurance. Also sells OTC supplements and skincare.", key_products_or_services: ["Telehealth consultations", "Hair loss Rx (finasteride, minoxidil)", "Sexual health Rx (sildenafil, tadalafil)", "Compounded GLP-1 weight loss drugs", "Skincare, mental health, supplements"], customer_type: "Millennials & Gen-Z wanting convenient, affordable healthcare", pass_fail: "YES" },
        step_2_check_the_financials: { latest_quarter: "Q3 2025", revenue_latest: "$599M", revenue_growth_yoy: "+49%", revenue_beat_miss: "BEAT", eps_latest: "$0.08", eps_beat_miss: "MISS (40%)", net_income_latest: "$15.8M", profitable: true, gross_margin: "74%", operating_margin_trend: "Compressing", debt_level: "LOW", free_cash_flow_latest: "$79.4M", cash_position: "$250M", financial_health_grade: "B", red_flags: ["Gross margin declining (79% → 74% YoY)", "Revenue per subscriber falling ($84 → $74)", "~35% of revenue from GLP-1s under legal threat", "EPS missed estimates by 40% in Q3"], green_flags: ["Revenue growing 49-111% YoY", "FCF positive at $79M/quarter", "2.5M subscribers and growing", "First GAAP profitable year in 2024"] },
        step_2a_earnings_and_guidance_review: { one_time_items: "GAAP vs Adjusted: Stock-based comp of $45M excluded from adjusted figures.", segment_breakdown: "Telehealth subscriptions: +52% YoY ($420M, 70% of rev). Weight loss: +180% YoY ($130M). Dermatology: +18% YoY ($49M).", guidance_changes: "FY2026 revenue guide: $2.3-2.5B (prev $2.1-2.3B). EPS: $0.35-0.50. [FORWARD-LOOKING]", management_tone: "Cautious — 'We remain confident in our core business, but acknowledge regulatory headwinds require us to diversify revenue streams.'", analyst_reaction: "2 downgrades post-earnings (Morgan Stanley, Jefferies). 1 upgrade (Piper Sandler). Avg PT cut from $45 to $28.", forward_statements_note: "All guidance and outlook flagged as [FORWARD-LOOKING] with significant regulatory uncertainty." },
        step_3_understand_the_story: { bull_case: "Scale leader in DTC telehealth with 2.5M subs. GLP-1 crackdown is temporary — core business (hair, skin, ED) was growing before weight loss. At $3.6B for a $2.3B rev company, absurdly cheap if the platform holds.", base_case: "Steady core growth.", bear_case: "Business model built on regulatory arbitrage — selling cheap copies of patented drugs. Novo suing, FDA cracking down, DOJ referred. If enforcement extends beyond GLP-1, entire model at risk.", what_must_go_right: ["Core non-GLP-1 subs keep growing", "Novo lawsuit settles reasonably", "FDA stays limited to GLP-1 enforcement", "Branded partnerships replace some revenue"], what_could_break_the_story: ["FDA bans all mass compounding", "DOJ opens criminal investigation", "Subscriber churn accelerates", "Brand permanently damaged"], macro_overlay: "GLP-1 regulation is the key macro driver for this sector currently.", catalyst_timeline: ["Feb 23: Q4 earnings release"] },
        step_4_know_the_risks: { top_risks: [{ risk: "Novo Nordisk patent lawsuit", severity: "CRITICAL", likelihood: "HIGH", explanation: "Could permanently ban all compounded semaglutide + damages" }, { risk: "FDA enforcement expansion", severity: "HIGH", likelihood: "MEDIUM", explanation: "If enforcement moves beyond GLP-1, entire compounding model breaks" }, { risk: "DOJ criminal referral", severity: "HIGH", likelihood: "HIGH", explanation: "HHS referred HIMS to DOJ — criminal investigation possible" }], ownership_signals: "Insider selling trend in late 2025.", regulatory_exposure: "EXTREME", concentration_risk: "~35% revenue from compounded GLP-1s under threat" },
        step_5_check_the_competition: { main_competitors: [{ name: "Ro (Roman)", why_compete: "Same DTC telehealth model", their_advantage: "More vertically integrated, pivoted to branded GLP-1 earlier" }], moat_strength: "WEAK", moat_explanation: "Strong brand and 2.5M subs, but limited pricing power. Generic drugs are commodities." },
        step_6_valuation_reality_check: { current_pe: "30.86x", forward_pe: "22.50x", sector_or_peer_avg_pe: "25x", price_to_sales: "1.5x", ev_ebitda_if_relevant: "10x", simple_dcf_implied_value: "TTM FCF $318M × 15% 5yr growth [ASSUMPTION] × 3% terminal [ASSUMPTION] × 10% discount = ~$22/share implied value", is_it_expensive: "CHEAP", valuation_context: "At 1.5x forward revenue, priced like a company in permanent decline.", bear_case_target: "$8-12", base_case_target: "$30", bull_case_target: "$55" },
        step_7_verdict: { action: "WATCH", confidence: "MEDIUM", one_line_reason: "Asymmetric setup, but buying before Feb 23 earnings is gambling.", what_signal_would_change_this: "Feb 23 earnings showing core sub growth + 2026 guidance", most_important_metric_to_track: "Non-GLP-1 subscriber net adds (Q4 2025)", suggested_revisit_date: "February 23, 2026" },
        investor_gut_check: { question_1: "Ready to hold?", question_2: "Upside?", question_3: "Lawsuit scope?", question_4: "Size?", mindset_reminder: "Stock-specific warning based on current situation" }
    },
    AAPL: {
        meta: { ticker: "AAPL", company_name: "Apple Inc.", sector: "Technology / Consumer Electronics", current_price: "$232.50", market_cap: "$3.5T", trailing_pe: "37.2", forward_pe: "32.1", fifty_two_week_range: "$169.21 - $260.10", avg_volume: "52.3M", beta: "1.1", report_date: "Feb 13, 2026", data_freshness_note: "Market close Feb 12, 2026" },
        step_1_know_what_you_own: { one_liner: "Apple makes iPhones, Macs, and iPads, and charges you monthly for services.", how_it_makes_money: "~52% from iPhone sales, ~25% from Services.", key_products_or_services: ["iPhone", "Services"], customer_type: "Global consumers", pass_fail: "YES" },
        step_2_check_the_financials: { latest_quarter: "Q1 FY2026", revenue_latest: "$124.3B", revenue_growth_yoy: "+4%", revenue_beat_miss: "BEAT", eps_latest: "$2.18", eps_beat_miss: "BEAT", net_income_latest: "$36.3B", profitable: true, gross_margin: "46.9%", operating_margin_trend: "Stable", debt_level: "MODERATE", free_cash_flow_latest: "$30.6B", cash_position: "$160B", financial_health_grade: "A", red_flags: ["China growth slowing"], green_flags: ["FCF positive", "Buybacks"] },
        step_2a_earnings_and_guidance_review: { one_time_items: "None notable. Clean GAAP quarter.", segment_breakdown: "iPhone: $69.1B (+1%). Services: $26.3B (+14%). Mac: $8.7B (+16%). iPad: $8.1B (+15%). Wearables: $12.1B (-2%).", guidance_changes: "No formal guidance given (Apple policy). Analysts expect Q2 rev ~$94B. [FORWARD-LOOKING]", management_tone: "Confident — 'Apple Intelligence is off to a very strong start and we're just getting started.'", analyst_reaction: "Broadly positive. 3 PT raises post-earnings. Consensus PT ~$255.", forward_statements_note: "Apple does not provide formal guidance. All estimates are consensus-based [FORWARD-LOOKING]." },
        step_3_understand_the_story: { bull_case: "Apple Intelligence supercycle.", base_case: "Steady growth.", bear_case: "Regulatory fees cut.", what_must_go_right: ["AI adoption"], what_could_break_the_story: ["China ban"], macro_overlay: "Tech regulation trends", catalyst_timeline: ["April Earnings"] },
        step_4_know_the_risks: { top_risks: [{ risk: "China", severity: "HIGH", likelihood: "MEDIUM", explanation: "Revenue drop" }], ownership_signals: "Stable", regulatory_exposure: "MODERATE", concentration_risk: "iPhone" },
        step_5_check_the_competition: { main_competitors: [{ name: "Samsung", why_compete: "Premium phones", their_advantage: "AI speed" }], moat_strength: "STRONG", moat_explanation: "Device ecosystem" },
        step_6_valuation_reality_check: { current_pe: "37.2x", forward_pe: "32.1x", sector_or_peer_avg_pe: "30x", price_to_sales: "8.5x", ev_ebitda_if_relevant: "25x", simple_dcf_implied_value: "TTM FCF $112B × 8% growth [ASSUMPTION] × 3% terminal × 10% discount = ~$210/share implied", is_it_expensive: "EXPENSIVE", valuation_context: "Trading at historical premium.", bear_case_target: "$180", base_case_target: "$230", bull_case_target: "$300" },
        step_7_verdict: { action: "WATCH", confidence: "HIGH", one_line_reason: "Great biz, full price.", what_signal_would_change_this: "Pullback to $200", most_important_metric_to_track: "Services growth", suggested_revisit_date: "April 2026" },
        investor_gut_check: { question_1: "Safe haven?", question_2: "Upside?", question_3: "Services?", question_4: "Size?", mindset_reminder: "Premium price" }
    },
    TSLA: {
        meta: { ticker: "TSLA", company_name: "Tesla, Inc.", sector: "Automotive / AI", current_price: "$345.20", market_cap: "$1.1T", trailing_pe: "155", forward_pe: "100", fifty_two_week_range: "$138.80 - $488.54", avg_volume: "78.5M", beta: "2.5", report_date: "Feb 13, 2026", data_freshness_note: "Market close Feb 12, 2026" },
        step_1_know_what_you_own: { one_liner: "Tesla makes EVs and develops AI/robots.", how_it_makes_money: "Car sales and energy storage.", key_products_or_services: ["EVs", "Energy"], customer_type: "Tech-savvy people", pass_fail: "YES" },
        step_2_check_the_financials: { latest_quarter: "Q4 2025", revenue_latest: "$25.7B", revenue_growth_yoy: "+2%", revenue_beat_miss: "MISS", eps_latest: "$0.72", eps_beat_miss: "MISS", net_income_latest: "$2.3B", profitable: true, gross_margin: "19.8%", operating_margin_trend: "Compressing", debt_level: "LOW", free_cash_flow_latest: "$2.0B", cash_position: "$34B", financial_health_grade: "C", red_flags: ["Margin compression"], green_flags: ["Energy growth"] },
        step_2a_earnings_and_guidance_review: { one_time_items: "$600M restructuring charge (Austin layoffs). Adjusted EPS $0.85 vs GAAP $0.72.", segment_breakdown: "Automotive: $19.8B (-3%). Energy/Storage: $3.1B (+67%). Services: $2.8B (+12%).", guidance_changes: "FY2026 deliveries: 2.1-2.3M vehicles (flat-ish). Energy: 100GWh target [FORWARD-LOOKING]", management_tone: "Defensive — 'The market doesn't appreciate the optionality in our robotaxi and Optimus programs.'", analyst_reaction: "Mixed. 2 downgrades (Goldman, UBS). 1 upgrade (Wedbush). Wide PT range: $85-$550.", forward_statements_note: "Robotaxi timeline and Optimus revenue projections are [FORWARD-LOOKING] with high uncertainty." },
        step_3_understand_the_story: { bull_case: "AI/Robot/Energy leader.", base_case: "Car company.", bear_case: "Commoditized auto.", what_must_go_right: ["Robotaxi"], what_could_break_the_story: ["Reg delay"], macro_overlay: "EV adoption rates", catalyst_timeline: ["2026 Robotaxi"] },
        step_4_know_the_risks: { top_risks: [{ risk: "Regs", severity: "CRITICAL", likelihood: "HIGH", explanation: "Robotaxi delay" }], ownership_signals: "Elon selling", regulatory_exposure: "HIGH", concentration_risk: "Elon key man" },
        step_5_check_the_competition: { main_competitors: [{ name: "BYD", why_compete: "Same market", their_advantage: "Cost" }], moat_strength: "MODERATE", moat_explanation: "Brand and data" },
        step_6_valuation_reality_check: { current_pe: "155x", forward_pe: "100x", sector_or_peer_avg_pe: "30x", price_to_sales: "10x", ev_ebitda_if_relevant: "50x", simple_dcf_implied_value: "TTM FCF $8B × 20% growth [ASSUMPTION] × 3% terminal × 12% discount (high beta) = ~$120/share implied", is_it_expensive: "SPECULATIVE", valuation_context: "AI premium priced in.", bear_case_target: "$150", base_case_target: "$300", bull_case_target: "$500" },
        step_7_verdict: { action: "WATCH", confidence: "LOW", one_line_reason: "Extreme valuation.", what_signal_would_change_this: "Margin recovery", most_important_metric_to_track: "Auto margins", suggested_revisit_date: "April 2026" },
        investor_gut_check: { question_1: "AI bet?", question_2: "Growth?", question_3: "Elon?", question_4: "Risk?", mindset_reminder: "High volatility" }
    }
};
